title: [Rexetin in the therapy of depressive states].
abstract: Rexetin was used in the dosage of 20-60 mg daily during 6 weeks in the treatment of 25 patients with depression. An efficacy of the therapy was evaluated by the Hamilton scales for Depression (HAM-D) and anxiety (HAM-A) and Montgomery-Asberg Scale (MADRS). Patients were considered as responders if they demonstrated the reduction of scores by 50%. Twenty-three responders (92.0%) were divided into 3 groups: the first--with immediate therapeutic response during 1-2 weeks (n = 8; 34.8%); the second--with positive dynamics at the 3rd week of the treatment (n = 9; 39.1%); the third group--with favorable results at the end of 5-6 week of the therapy (n = 6; 26.1%). The clinical predictors of different therapeutic responses during short-term therapy were as follows: severity of depressive episode, hypotimia of modality (anxiety, anxiety-sorrow); vitalization of verbal/ nonverbal sorrow affect; presentation of autonomic (somatic) appearances of generalized anxiety disorder; ranks of typical depressive symptoms in subjective perception of patients; character of sleep disorders, presence of atypical depressive symptoms, in particular a disturbance of interpersonal relations due to elevated irritability; localization and extent of generalization of pathological body sensations; dominant content of obsessive anxiety; a type of affective triad; panic attacks, with- or without agoraphobia, concomitant to depressive disorder. In the total group of responders, there was a simultant (harmonic) reduction of the total score on the depression and anxiety scales (65.2%) and the anticipating anxiolytic or thymoanaleptic effect of the drug was observed less often (34.8%).
authors.forename: A S
authors.initials: AS
authors.lastname: Bobrov
authors.forename: O V
authors.initials: OV
authors.lastname: Petrun'ko
authors.forename: A V
authors.initials: AV
authors.lastname: Kovaleva
authors.forename: O N
authors.initials: ON
authors.lastname: Pavlova
mesh_terms: D000328:Adult; D003866:Depressive Disorder / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors